Dr David Eagle on Celebrating 20 Years of COA at This Year’s Meeting
March 15th 2023In this preview of the 2023 Community Oncology Conference, past president of the Community Oncology Alliance, David Eagle, MD, of New York Cancer & Blood Specialists, discusses what has him excited for this year's meeting, both sessions and speakers.
Watch
Dermatologists’ Focus to Delve Below the Skin at Annual Conference
March 14th 2023The 2023 American Academy of Dermatology Annual Meeting, held in New Orleans, Louisiana, from March 17-21, 2023, will feature research and presentations exploring the mechanisms, presentation, and treatment of dermatological disorders.
Read More
Dr John Harris: There Are a Lot of Reasons to Talk About Vitiligo at This Year’s AAD Meeting
March 14th 2023There is a lot to talk about in the vitiligo space at this year’s annual meeting of the American Academy of Dermatology (AAD), said John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School.
Watch
Even Oncologists Sold on Value-Based Care Hesitate to Embrace the EOM
March 10th 2023Members of the Association of Community Cancer Centers (ACCC) Alternative Payment Coalition discussed strategies for succeeding in value-based care and voiced concerns surrounding the upcoming Enhancing Oncology Model (EOM) during a panel discussion at the ACCC 2023 Annual Meeting and Business Summit.
Read More
Highlands Oncology Group’s Jeff Hunnicutt Discusses Risk Under the EOM
March 10th 2023Jeff Hunnicutt, CEO of Highlands Oncology Group, explains the 2 risk options provided under the Enhancing Oncology Model (EOM) and why the mandatory downside risk might give pause to practices that saw some success in the Oncology Care Model.
Watch
Dr Sigrun Hallmeyer Discusses Use of Precision Medicine in the First-line Setting
March 10th 2023As scientists are identifying molecular alterations in patients with later-stage cancers that may be targets in earlier-stage disease, next-generation sequencing is being utilized more in the first-line setting, noted Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.
Watch
Dr Kevin Davies: There Is Great Potential for CRISPR in Genetic Diseases and Cancers
March 9th 2023Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR has evolved from the initial discovery of the double helix to now, with the technology holding great promise for both genetic diseases and cancers.
Watch
Multicancer Early Detection May Change the Screening Game—If We Learn From the Past
March 9th 2023A session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit addressed the promise and potential drawbacks of multicancer early detection (MCED) testing for patients in the primary care setting.
Read More
Dr Andre Harvin: Pharmacists Play a Critical Role in Oncology Care
March 9th 2023Andre Harvin, PharmD, MS, MBA, Cone Health Cancer Center, discusses the vital role of pharmacists in oncology: how they use data to streamline patient visits, work to facilitate patient access to biosimilars, and advocate for their patients.
Watch
Dr Ajai Chari: Patients in High-risk Subgroups Benefited From Daratumumab Plus Triplet
March 9th 2023Ajai Chari, MD, professor of medicine and director of clinical research in the Multiple Myeloma Program at Mount Sinai in New York, discusses a post-hoc analysis of data from the phase 2 GRIFFIN trial.
Read More
Dr Clyde Yancy: Redefine Greatness Through a Quest for Health Equity in Heart Failure
March 8th 2023Speaking at the 72nd American College of Cardiology Scientific Session in New Orleans on Sunday, Clyde W. Yancy, MD, MSc, the vice dean for diversity and inclusion at the Feinberg School of Medicine at Northwestern University, challenged the audience to rethink what success looks like in health care.
Read More
Results for the STELLAR trial, presented at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology, hit nearly every mark: patients taking sotatercept improved their performance on a 6-minute walk test by 40.8 meters, which was the primary end point, and achieved 8 of 9 secondary end points.
Read More
Dr Olalekan Ajayi Previews the 2023 ACCC Annual Meeting
March 6th 2023Olalekan Ajayi, PharmD, MBA, chief operating officer of Highlands Oncology Group, PA, and 2023-2024 president-elect of the Association of Community Cancer Centers (ACCC), discusses why he is excited for this year’s meeting, including its many workshops and day 1 keynote on CRISPR.
Watch
ACCC Meeting to Highlight Technological Advances and Care Delivery Models in Oncology
March 6th 2023The Association of Community Cancer Centers (ACCC) 49th Annual Meeting and Cancer Center Business Summit will feature presentations and interactive workshops centered on the latest in technology, care delivery, and payment issues in oncology.
Read More
HALO Misses End Point, but Optimism Remains for Baxdrostat in Resistant Hypertension
March 5th 2023Baxdrostat is a highly selective aldosterone synthase inhibitor; phase 1 studies showed that the therapy caused a sustained, dose-dependent reduction in plasma aldosterone by more than 70% without reducing cortisol.
Read More
Bempedoic Acid, Approved to Treat LDL Cholesterol, Cuts Risk of Major CV Events by 13%
March 4th 2023Results from the CLEAR Outcomes trial were presented today at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology. Plans for a broader label are in the works.
Read More
Dr Deepak Bhatt Discusses Results From the ENTRIGUE Trial
March 2nd 2023Deepak L. Bhatt, MD, MPH, Icahn School of Medicine at Mount Sinai, has multiple presentations during the upcoming American College of Cardiology Scientific Sessions, including additional phase 2 results from the ENTRIGUE trial for pegozafermin in severe hypertriglyceridemia.
Watch
ACCESS Tests Effect of Eliminating Co-pay on CV Outcomes
March 1st 2023Braden Manns, MD, MSc, a nephrologist and health economics researcher at the University of Calgary in Canada, will present the results of a randomized trial evaluating the impact of removing co-payments for drugs that treat chronic conditions on cardiovascular outcomes during the American College of Cardiology Scientific Sessions in New Orleans, Louisiana, on Sunday, March 5.
Watch
Panel Addresses How Payers, Providers Can Optimally Use Real-World Evidence to Advance Cancer Care
February 23rd 2023Utilizing real-world evidence that applies to the specific care needs of certain patient populations can promote timely decision-making among payers and providers on the use of effective cancer therapies available on the market, said panelists at the 2022 Patient-Centered Oncology Care® (PCOC) meeting.
Read More
BRVO, CRVO Need More Effective Long-term Therapies
February 12th 2023While the current therapies are effective for treating branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), they are inadequate for long-term treatment in clinical practice, according to an analysis of real-world data.
Read More
High-Dose Aflibercept in Wet AMD and DME Provides Therapeutic Benefits, No New Safety Signals
February 12th 2023Two studies looking at a higher dose of aflibercept found that an 8-mg dose can be maintained at longer dosing intervals with similar benefits and no additional safety signals compared with the 2-mg dose.
Read More
Anti-VEGF Therapy vs Gold Standard in Preterm Babies With ROP: Dr Darius Moshfeghi
February 11th 2023The BUTTERFLEYE trial sought to determine if aflibercept, an anti–vascular endothelial growth factor (anti-VEGF) therapy, was equivalent to laser photocoagulation, the gold standard to treat retinopathy of prematurity (ROP) in preterm babies.
Read More